Virtual Reality-Integrated Propulsion Feedback for Stroke Rehab

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20+
SponsorThe University of Texas Medical Branch, Galveston

About this trial

This study evaluates a novel Virtual Reality (VR)-integrated visual feedback system designed to enhance limb propulsion during robot-assisted gait rehabilitation in individuals post-stroke. In collaboration with CUREXO, a rehabilitation robotics company, the system is embedded within the Morning Walk® end-effector robot and provides real-time visual feedback to facilitate symmetrical use of the paretic and non-paretic limbs. The goal is to address gait asymmetry commonly observed in hemiparetic stroke survivors by promoting improved paretic leg propulsion, which is a key contributor to forward movement during walking.

A total of 30 participants (15 stroke, 15 healthy controls) aged 20 years or older will undergo single-session gait training using the VR-robot system. Participants will be assessed using spatiotemporal gait parameters, muscle activity, foot pressure, and vertical ground reaction forces. Additional safety measures-including a saddle-type weight support and real-time heart rate monitoring via smartwatch-are implemented to ensure a safe and controlled training environment. This study aims to test the feasibility and effectiveness of this VR-based system in improving gait symmetry and functional walking capacity in people recovering from stroke.

Eligibility criteria

Qualifiers

Adults aged 20 years or older.

Diagnosis of stroke at least 1 month prior to participation.

Able to walk at least 10 meters with or without assistive devices.

Disqualifiers

Individuals with a life expectancy of less than one year.

Comatose individuals.

Individuals unable to follow three-step commands.

Individuals with lower limb amputation.

Trial design

Treatments tested in this trial

  • VR-Based Gait Training with End-Effector Robot

Treatment groups

30 Participants
are divided into 2 treatment groups